Aclaris Therapeutics, which is developing a proprietary hydrogen peroxide solution for common skin lesions, announced terms for its IPO on Friday.
The Malvern, PA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Aclaris Therapeutics would command a fully diluted market value of $301 million.
Aclaris Therapeutics, which was founded in 2012, plans to list on the Nasdaq under the symbol ACRS. Jefferies and Citi are the joint bookrunners on the deal. It is expected to price during the week of October 5, 2015.
The article Skin in the game: Aclaris Therapeutics sets terms for $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.